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Abstract
Background: Migraine, a common chronic-intermittent disorder of idiopathic origin characterized by severe
debilitating headaches and autonomic nervous system dysfunction, and placental abruption, the premature
separation of the placenta, share many common pathophysiological characteristics. Moreover, endothelial
dysfunction, platelet activation, hypercoagulation, and inflammation are common to both disorders. We assessed
risk of placental abruption in relation to maternal history of migraine before and during pregnancy in Peruvian
women.
Methods: Cases were 375 women with pregnancies complicated by placental abruption, and controls were 368
women without an abruption. During in-person interviews conducted following delivery, women were asked if
they had physician-diagnosed migraine, and they were asked questions that allowed headaches and migraine to
be classified according to criteria established by the International Headache Society. Logistic regression procedures
were used to calculate odds ratios (aOR) and 95% confidence intervals (CI) adjusted for confounders.
Results: Overall, a lifetime history of any headaches or migraine was associated with an increased odds of
placental abruption (aOR = 1.60; 95% CI 1.16-2.20). A lifetime history of migraine was associated with a 2.14-fold
increased odds of placental abruption (aOR = 2.14; 95% CI 1.22-3.75). The odds of placental abruption was 2.11
(95% CI 1.00-4.45) for migraineurs without aura; and 1.59 (95% 0.70-3.62) for migraineurs with aura. A lifetime
history of tension-type headache was also increased with placental abruption (aOR = 1.61; 95% CI 1.01-2.57).
Conclusions: This study adds placental abruption to a growing list of pregnancy complications associated with
maternal headache/migraine disorders. Nevertheless, prospective cohort studies are needed to more rigorously
evaluate the extent to which migraines and/or its treatments are associated with the occurrence of placental
abruption.
Background
Placental abruption, the premature separation of the
placenta before delivery of the fetus, complicates
approximately 1% of all pregnancies [1-3]. Placental
abruption is a significant cause of maternal and neonatal
morbidity and infant mortality. Maternal complications
include hemorrhagic shock, coagulopathy, disseminated
intravascular coagulation, and renal failure. The condi-
tion is also associated with increased risks of preterm
delivery and intrauterine growth restriction. Neonatal
death and long term complications are also adverse
outcomes following placental abruption [4,5]. Although
placental abruption accounts for a significant proportion
of maternal and fetal morbidity and mortality, the etiol-
ogy of this important obstetrical complication remains
largely speculative. Evidence from studies conducted
during the last three decades, however, suggest that
hypertensive disorders, increased maternal age, grand-
multiparity, thrombophilia, cigarette smoking, illicit drug
use, particularly cocaine, and external trauma to the
abdomen are associated with an increased risk of pla-
cental abruption [2,5-7]. Other putative risk factors
include maternal iron deficiency anemia [8], maternal
psychiatric disorders including depression [9], hyperho-
mocystinemia [10], as well as maternal infection and/or
inflammation [11]. Results from molecular epidemiology
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ways (e.g., coagulation, fibrinolysis, platelet function,
infection/inflammation, angiogenesis, and the renin-
angiotensin systems) may also be important genomic
risk factors of placental abruption [12-14]. On balance,
available epidemiological and clinical data suggest that
vascular dysfunction manifesting as impaired uteropla-
cental perfusion may be of etiologic importance in pla-
cental abruption.
Migraine, a common chronic-intermittent neurovascu-
lar headache disorder, is ranked among the world’s
twenty most disabling medical conditions by the World
Health Organization [15]. Migraine is characterized by
episodic severe headache accompanied by autonomic
nervous system dysfunction. Some patients with
migraine have headaches that are accompanied by tran-
sient neurological symptoms and are thus classified as
having migraine with aura [16]. Women are more com-
monly affected than men, with reported lifetime preva-
lence estimates of 16-32% for women and 6-9% for
men [17]. Migraine risk varies considerably across the
life course and is most prevalent among women during
their childbearing years [18,19]. Associations between
migraine and vascular disease have long been hypothe-
sized and considered over the last century, but results
reported in the epidemiologic literature are contradic-
t o r y .H o w e v e r ,e v i d e n c ef r o m more recent rigorously
designed, conducted and analyzed studies now suggest
consistent relationships between migraine and vasospas-
tic disorders such as variant angina and Raynaud’s
phenomenon, as well as ischemic stroke in young
women [20,21]. A recent population-based cross-sectional
study of Dutch adults found that female migraineurs were
at increased risk of subclinical brain infarcts and white
matter lesions (OR = 2.1; 95% CI, 1.0-4.7), which may
increase the risk of future stroke and dementia [22].
After decades of believing that migraine had no adverse
effects on pregnancy and parturition [23,24], a conclusion
based on relatively few studies with conflicting results,
more recent studies have documented elevated risks of
preterm delivery [25], low birth weight [25] and preg-
nancy-induced hypertension and preeclampsia among
women with migraine [19,25-28]. To date, however, no
investigators have evaluated the association between
migraine and placental abruption risk. Because emerging
evidence suggest that placental abruption is an ischemic
placental disease with epidemiological and pathophysio-
logical characteristics similar to preterm delivery, intrau-
terine growth restriction and preeclampsia [2,29], we
hypothesized that pregnant migraineurs, compared with
those without the condition would have an elevated risk
of placental abruption. To test this hypothesis, we ana-
lyzed data from a large case-control study of placental
abruption conducted in Lima, Peru.
Methods
Study population
This case-control study was conducted at the Hospital
Nacional dos de Mayo, Instituto Especializado Materno
Perinatal, Hospital Edgardo Rebagliati Martins, Hospital
Nacional Hipolito Unanue, and Hospital Nacional Doc-
ente Madre Niño San Bartolomè in Lima, Peru, from
September 2006 through September 2008. This study
was approved by the institutional review board of each
participating institution. All participants provided writ-
ten informed consent.
Placental abruption cases were identified by daily
monitoring of all new admissions to antepartum, emer-
gency room, and labor and delivery wards of participat-
ing hospitals. Study subjects were recruited during their
hospital stay. Hospital medical records were reviewed so
that clinical diagnostic signs, symptoms and physical
characteristics of placental abruption could be objec-
tively confirmed; and so that other clinical diagnoses
associated with late pregnancy vaginal bleeding could be
excluded. During the study period, there were an esti-
mated total of 55,802 deliveries of which 452 were com-
plicated by placental abruption. Twenty-eight cases were
missed because of inadequate staffing. Of the remaining
424 cases approached, 382 (90%) elected to participate
in the study. The diagnosis of placental abruption was
based on routine clinical examination performed by the
attending physician. For the diagnosis of placental
abruption, we required evidence of blood clot (retropla-
cental clots) or bleeding behind the placenta accompa-
nied by at least 2 of the following signs and symptoms:
1) vaginal bleeding in late pregnancy that was not asso-
ciated with placenta previa or cervical lesions; 2) uterine
tenderness and/or abdominal pain; and 3) fetal distress
or death. Controls were selected from eligible women
who delivered at the participating hospitals during the
study period. Following the recruitment of a placental
abruption case, a control patient was sought for recruit-
ment from the same hospital. Potential controls were
identified by reviewing daily delivery logs in participat-
ing hospitals. Eligible controls were women who did not
have a diagnosis of placental abruption and whose medi-
cal record review later confirmed this fact. Of the 429
controls approached, 86% (n = 369) agreed to partici-
pate in the study.
Data collection and variable specification
We used a standardized, structured Spanish-language
questionnaire to collect information regarding maternal
sociodemographic, medical, reproductive, and lifestyle
characteristics during in-person interviews. All inter-
views were conducted in the hospital by trained research
interviewers. All interviews were conducted in Spanish.
Information collected during the interviews included
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pregnancy, medical history, and smoking and alcohol
consumption during pregnancy.
Information about headache and migraine symptoms
were collected using the decode Genetics migraine ques-
tionnaire [30] which was translated to Spanish for use in
Lima, Peru. Women were asked whether they had ever
experienced headache attacks. For those answering yes,
separate questions were asked about (i)a g eo fo n s e to f
first attack, (ii) timing of last attack; (iii) typical duration
of attacks; iv) whether they had ever been diagnosed as
having migraine by a doctor; and (v) age at diagnosis.
Women were also asked to indicate characteristics
symptoms associated with their headaches. These
included location of pain, visual disturbances including
flares or zigzag patterns, sensory disturbances including
progressive numbness over the face and body, difficulty
with speech, inhibition of daily activity, and triggers of
headaches. Collected information allowed us to classify
women for several headache and migraine variables.
Women were classified as ever having headache before
(yes, no) or during pregnancy (yes, no). Those women
with headaches were classified according to the timing
of onset (never, final month of pregnancy, first 8
months of pregnancy and prior to pregnancy) relative to
the index pregnancy. We classified women according to
whether they had been diagnosed, by a physician, as
having migraine (yes, no). Wea l s ow e r ea b l et oc l a s s i f y
women based on the modified International Classifica-
tion of Headache Disorders-II (ICHD-II) criteria for
migraine [31]. “Strict Migraine” (ICHD-II category 1.1
or 1.2) was defined by at least 5 lifetime headache
attacks lasting 4-72 hours, with at least 2 of the qualify-
ing pain characteristics (unilateral location, pulsating
quality, moderate or severe pain intensity, aggravation
by routine physical exertion), at least one of the asso-
ciated symptoms (nausea and/or vomiting, photo/pho-
nophobia), and not readily attributable to another
central nervous system disorder or head trauma (accord-
ing to subject self-report). “Probable Migraine” (ICHD-II
category 1.6) was designated if all but one of the strict
migraine criteria were fulfilled, excluding headaches
attributable to another disorder. Subjects classified as
strict or probable migraine were combined for further
analysis. We included both “Strict Migraine” and “Prob-
able Migraine” as migraineurs for these analyses. Migrai-
neurs were further classified as “migraine with aura” and
“migraine without aura” according to ICHD-II diagnos-
tic criteria [31]. Women with non-migrainous headaches
were classified as having “Tension-type Headaches” or
“Other Headaches” according to ICHD diagnostic
criteria.
We used the Patient Health Questionaire-9 (PHQ-9)
to assess participants’ experience of depression or
depressive symptoms during pregnancy. The instrument
has been demonstrated to be a reliable tool for assessing
recent psychosocial stressors among obstetrics-gynecol-
ogy patients [32] and in Spanish-speaking women [33].
In a recent validation study of the PHQ-9 questionnaire,
the authors concluded that the instrument is a reliable
and valid measure of depression severity and a useful
clinical and research tool [34]. The PHQ-9 scale
includes nine items, and choices for responses were a)
never; b) several weeks over the pregnancy; c) more
than half the pregnancy; or d) nearly the whole preg-
nancy. The PHQ-9 total score is the sum of scores for
the nine items for each woman, and ranged from 0-27.
We categorized participants as exhibiting symptoms
consistent with a diagnosis of moderate or severe
depression (PHQ-9 score ≥ 10) [34].
Maternal and infant records were reviewed to collect
detailed information concerning antepartum, labor, and
delivery characteristics, as well as conditions of the new-
born. Maternal anthropometric measures (height,
weight, and mid-arm circumference) were taken during
participants’ hospital stays. Gestational age was based on
the date of the last menstrual period and was confirmed
by an ultrasound examination before 20 weeks. Pre-
pregnancy body mass index (BMI), a measure of overall
maternal adiposity, was calculated as (self-reported)
weight in kilograms divided by height in meters squared.
Women were classified as lean (BMI < 19.8 kg/m
2), nor-
mal (BMI = 19.8-26.0 kg/m
2), overweight (BMI = 26.1-
29.0 kg/m
2) or obese (BMI > 29.0 kg/m
2).
Analytical population
The analytical population for the study is derived from
the 382 placental abruption cases and 369 controls
enrolled in the study. For the purposes of the present
study, 8 women with twin or higher-order pregnancies
(7 cases and 1 control) were excluded, leaving 375 pla-
cental abruption cases and 368 controls for analysis.
Statistical analysis
We examined the frequency distribution of maternal
socio-demographic characteristics and reproductive his-
tories according to case and control status. Initial bivari-
ate analyses were carried out to determine unadjusted
odds ratio (OR) and 95% confidence interval (CI). Effect
modification was evaluated by stratified analyses and by
including appropriate interaction terms in logistic
regression models [35]. On the basis of a prior literature
[6,7,9], we conducted exploratory analyses to evaluate
the extent to which observed associations between pla-
cental abruption and migraine status were modified by
maternal age, pre-pregnancy overweight status, depres-
sion, and hypertensive status. If there appeared to be
no effect modification (p-value for cross-product term
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simultaneously control for confounding variables while
estimating ORs and 95% CIs.
We selected potential confounders from a list of vari-
ables for which there is evidence of possible associations
with migraine and placental abruption (from prior pub-
lished studies) and that met criteria for confounding
based on a review of the literature and assessment of
potential causal relationships based on prior knowledge.
We then controlled for potential confounders that chan-
ged multivariable ORs by ≥ 10% relative to the unad-
justed OR (35). Final logistic regression models included
confounders, as well as those covariates of a priori inter-
est (i.e., maternal age, maternal educational attainment,
maternal smoking status and alcohol consumption).
Maternal employment status, parity, pre-pregnancy body
mass index, and prenatal vitamins use were not found
to be confounders and thus were not included in final
models. All continuous variables are presented as mean
± standard deviation (SD). All reported p-values are
two-tailed.
Prior to initiating the study, we estimated that a study
size of 300 cases and an equal number of controls
would be sufficient (> 80% power) for estimating odds
ratios of ≥ 2.0 if exposure frequencies were ≥ 10%, and
if significance was set at 0.05. All analyses were per-
formed using STATA 9.0 statistical software (Stata, Col-
lege Station, Texas, USA).
Results
Forty-nine participants (37 cases, 12 controls) were clas-
sified as having “Strict Migraine"; and 18 participants (7
cases, 11 controls) were classified as having “Probable
Migraine”. Migraineurs were further classified as
“migraine with aura” (n = 32) and “migraine without
aura” (n = 35) according to ICHDII diagnostic criteria
(31). Socio-demographic and reproductive characteristics
of placental abruption cases and controls are presented
in Table 1. Cases and controls were similar with regards
to maternal age, parity, marital status and educational
attainment. Compared with controls, cases were less
likely to have received prenatal care. As expected, pla-
cental abruption cases were more likely to deliver pre-
term and low birth weight infants and to have a history
of hypertensive disorders. Approximately 15.7% of pla-
cental abruption cases delivered stillborn infants; there
were no stillbirth among controls.
The lifetime prevalence of headaches or migraine was
40.0% for placental abruption cases and 29.6% for con-
trols (Table 2). After adjusting for maternal age, prenatal
care enrollment and maternal depression status, mater-
nal lifetime history of headaches or migraine was asso-
ciated with an increased odds of placental abruption
(aOR = 1.60; 95% CI 1.16-2.20). A lifetime history of
migraine was associated with a 2.14-fold increased odds
of placental abruption (aOR = 2.14; 95% CI 1.22-3.75).
The odds of placental abruption was 2.11 (95% CI 1.00-
4.45) for migraineurs without aura; and 1.59 (95% 0.70-
3.62) for migraineurs with aura. A lifetime history of
tension-type headache was also increased with placental
abruption (aOR = 1.61; 95% CI 1.01-2.57). Other non-
migrainous headaches were only marginally and statisti-
cally nonsignificantly related with the odds of placental
abruption (aOR = 1.35; 95% CI 0.87-2.09). When reports
of migraine were grouped according to when they
started, the association with placental abruption was evi-
dent for migraine with onset during pregnancy (aOR =
2.63; 95% CI 0.48-14.44) and migraine with onset prior
to pregnancy (aOR = 1.79; 95% CI 0.98-3.27) although
these associations did not reach statistical significance.
The prevalence of physician-diagnosed migraine was
low in this study population (6.7% of placental abruption
cases and 5.4% of controls). History of physician-diag-
nosed migraine was associated with a modest but non-
significant increased odds of placental abruption (OR =
1.24; 95% CI 0.68-2.28). The association was further
attenuated after adjusting for confounding by maternal
age, use of prenatal care, and depression status (aOR =
1.13; 95% CI 0.60-2.12).
Inferences from this analysis are limited by the small
numbers of women with physician-diagnosed migraine.
We found no evidence of effect modification by
maternal pre-pregnancy overweight status or advanced
maternal age. We did however, find some evidence sug-
gestive of effect modification by maternal depressive
symptoms (Table 3) and by maternal hypertensive status
(Table 4). It appeared that women with migraine or
headache disorders and depression had a greatly
increased odds of placental abruption (aOR = 14.98;
95% CI 1.91-117.39) (Table 3). Similarly, women with
migraine and hypertensive disorders had a substantially
increased odds of placental abruption (aOR = 13.83;
95% CI 3.13-61.11) (Table 4). Inferences from these
exploratory analyses, however, were limited by the small
numbers of participants with co-morbid migraine and
depression and co-morbid migraine/headaches and
hypertensive disorders.
Discussion
To the best of our knowledge, this is perhaps the first
study to report the associations of headaches and
migraine and placental abruption risk. We found that
women with migraine had an increased odds of placen-
tal abruption. Because this study may be one of the first
to investigate whether maternal migraine status is asso-
ciated with placental abruption, our findings can only
tentatively be compared with studies that have investi-
gated other perinatal outcomes.
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adverse reproductive outcomes [16,25-27]. Our findings
are generally consistent with other studies reporting
associations of migraine with adverse pregnancy out-
comes including preterm birth [25], low birthweight
[26] and preeclampsia [25-28]. In their population-based
study of Taiwanese women, Chen et al. [25] reported
increased risks of preterm birth (aOR = 1.24; 95% CI
1.13-1.39) and low birthweight (aOR = 1.16; 95% CI
1.03-1.31) deliveries among mothers with migraine as
compared with non-migraineurs. Stronger associations
between maternal migraine status and risk of low birth-
weight deliveries (aOR = 1.84; 95% CI 0.90-3.77) were
reported from a study of Italian women [26]. Facchinetti
et al [26], recently reported from their prospective
cohort study of 702 normotensive pregnant women that
Table 1 Socio-Demographic and Reproductive Characteristics and Infant Outcomes in the Study Population, Lima,
Peru, 2006-2008
Characteristics Placental Abruption
Cases (N = 375) Controls (N = 368)
n % n % p-value
Maternal Age at Delivery (years) 28.4 ± 6.7
1 28.0 ± 6.3 0.38
Maternal Age at Delivery (years)
<20 39 10.4 30 8.2 0.30
20-29 174 46.4 191 51.9
30-34 86 22.9 78 21.2
≥35 75 20.0 67 18.2
Missing 1 0.3 2 0.5
Parity 1.32 ± 1.50
1 1.46 ± 1.51 0.19
0 161 42.9 146 39.7 0.63
1-2 143 38.1 145 39.4
≥3 71 18.9 77 20.9
≤ High School Education 241 64.3 216 58.7 0.29
Employed during Pregnancy 186 49.6 176 47.8 0.66
Planned Pregnancy 133 35.5 115 31.3 0.47
No Prenatal Care 41 10.9 22 6.0 0.02
No Prenatal Vitamin 57 15.2 45 12.2 0.38
Smoking during Pregnancy 8 2.1 6 1.6 0.48
Alcohol use during Pregnancy 35 9.3 30 8.2 0.67
Illicit Drug use during Pregnancy 2 0.5 1 0.3 - - -
Depressive Symptoms
3 33 8.8 10 2.7 < 0.001
Pre-pregnancy Body Mass Index (kg/m
2) 23.7 ± 3.7
1 23.4 ± 3.5 0.31
Pre-pregnancy Body Mass Index (kg/m
2)
<19.8 39 10.4 38 10.3 0.38
19.8-26.0 227 60.5 245 66.6
26.1-29.0 47 12.5 36 9.8
≥29.0 27 7.2 25 6.8
Missing 35 9.3 24 6.5
Chronic Hypertension 20 5.3 10 2.7 0.07
Preeclampsia or Eclampsia 98 26.1 11 3.0 < 0.001
Previous History of Placental Abruption 2 0.9 1 0.5 0.62
Infant Birth Weight (grams)
2 2438 ± 860
1 3306 ± 502 < 0.001
Low Birth Weight Infant (<2500 grams)
2 196 52.3 17 4.6 < 0.001
Gestational Age at Delivery (weeks)
2 35.3 ± 3.8
1 38.7 ± 1.8 < 0.001
Preterm Delivery Infant (<37 weeks)
2 204 54.4 20 5.4 < 0.001
C-Section Delivery 357 95.3 144 39.1 < 0.001
Stillbirth Delivery 59 15.7 0 0.0 - - -
1Mean ± SD (SD: standard deviation).
2Restricted to live birth only (314 cases and 368 controls).
3PHQ-9 depression symptom score ≥ 10, consistent with moderate or severe depression.
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developing hypertensive disorders of pregnancy (aOR =
2.85; 95% CI 1.40-5.81), as compared with non-migrai-
neurs. These findings corroborate results from earlier
case control studies conducted in Canada, the US, and
Peru [27,28]. Collectively, these studies suggest that
risks for adverse perinatal outcomes are increased with
maternal prior diagnosis of migraine. Notably, the asso-
ciation between placental abruption and migraine are of
similar magnitudes to associations reported previously
for placental abruption, such as diabetes mellitus,
advanced maternal age, and cigarette smoking during
pregnancy [12].
This study has several strengths, including the rela-
tively large sample of placental abruption cases and con-
trols, the fact that a well structured standardized
questionnaire was used to collect information suitable
for classifying migraine according to established ICHD-
II diagnostic criteria [31], and we were able to estimate
placental abruption risk according to the timing of
Table 2 Unadjusted and Adjusted Odds Ratio (OR) and 95% Confidence Interval (CI) for Placental Abruption in
Relation to Maternal History of Headaches and Migraine, Lima, Peru, 2006-2008
Placental Abruption
Cases (N = 375) Controls (N = 368)
Exposure Status n % n % Unadjusted
OR (95% CI)
1Adjusted
OR (95% CI)
Lifetime History of Headaches and Migraine (ICHD Criteria)
No 225 60.0 259 70.4
Yes 150 40.0 109 29.6 1.58 (1.17-2.15) 1.60 (1.16-2.20)
Migraine headache 44 11.7 23 6.3 2.20 (1.29-3.76) 2.14 (1.22-3.75)
Tension-type headaches 51 13.6 38 10.3 1.54 (0.98-2.44) 1.61 (1.01-2.57)
Other headaches 55 14.7 48 13.0 1.32 (0.86-2.02) 1.35 (0.87-2.09)
Lifetime History of Migraine with aura(ICHD criteria)
2
No Headaches or Migraine 225 60.0 259 70.4 1.00 (referent) 1.00 (referent)
Migraine without aura 23 6.1 12 3.3 2.21 (1.07-4.53) 2.11 (1.00-4.45)
Migraine with aura 21 5.6 11 3.0 2.20 (1.04-4.66) 1.59 (0.70-3.62)
Onset of Migraine (ICHD criteria)
2
No Headaches or Migraine 225 60.0 259 70.4 1.00 (referent) 1.00 (referent)
Yes, onset during pregnancy 5 1.3 2 0.5 2.88 (0.55-14.98) 2.63 (0.48-14.44)
Yes, onset prior to pregnancy 39 10.4 21 5.7 2.14 (1.22-3.74) 1.79 (0.98-3.27)
Headache or Migraine Onset
No headache 225 60.0 259 70.4 1.00 (referent) 1.00 (referent)
Final month of pregnancy 5 1.3 3 0.8 1.92 (0.45-8.12) 1.67 (0.39-7.24)
First 8 months of pregnancy 34 9.1 24 6.5 1.63 (0.94-2.83) 1.62 (0.92-2.85)
Prior to pregnancy 111 29.6 82 22.3 1.56 (1.11-2.18) 1.66 (1.16-2.37)
History of Physician Diagnosed Migraine
No 350 93.3 348 94.6 1.00 (referent) 1.00 (referent)
Yes 25 6.7 20 5.4 1.24 (0.68-2.28) 1.13 (0.60-2.12)
1Adjusted by maternal age, education, smoking status, alcohol consumption, prenatal care utilization and maternal depression status.
2Women with non-migrainous headache disorders were deleted from this analysis; column percentages will not sum to 100%.
Table 3 Unadjusted and Adjusted Odds Ratio (OR) and 95% Confidence Interval (CI) for Placental Abruption in
Relation to Maternal History of Headaches/Migraine and Depression Status, Lima, Peru, 2006-2008
Headaches/Migraine & Depression Status Placental Abruption
Cases (N = 375)
n
Controls (N = 368)
n
1Adjusted OR (95% CI)
No Headaches/Migraine & No Depression 213 257 1.00 (referent)
Yes Headaches/Migraine & No Depression 32 22 1.86 (1.03-3.34)
No Headaches/Migraine & Yes Depression 12 2 7.31 (1.01-33.31)
Yes Headaches/Migraine & Yes Depression 12 1 14.98(1.91-117.39)
P-value for the multiplicative interaction term 0.31
Two cases excluded because of missing depression information.
1Adjusted by maternal age, education, smoking status, alcohol consumption and prenatal care utilization.
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high participation rates for cases and controls (90% and
86%) also served to attenuate concerns about selection
bias. Several limitations, however, should be considered
when interpreting study findings. First, the case-control
study design and our reliance on self-reported signs and
symptoms of migraine and headaches (using a question-
naire that was not validated in the specific study popula-
tion) raises concerns about recall bias. To help mitigate
the likelihood of systematic reporting errors, well-
trained interviewers used a standard questionnaire to
collect information from study participants. Moreover,
neither the interviewers nor the participants were aware
of any of the specific study hypotheses. Random misclas-
sification (i.e., unrelated to placental abruption case-con-
trol status) of the onset, timing and intensity of
symptoms, however, may have occurred due to recall
error. Such errors in recall may have led to an underes-
timation of the odds ratios. Nevertheless, prospective
cohort studies that allow for clinical confirmation of
participants’ migraine status are needed to confirm or
refute our study findings. Second, we had no informa-
tion about maternal use of medications to treat
migraine. Future studies will have to include this infor-
mation so that independent and joint effects of maternal
migraine and medication use on placental abruption can
be evaluated. Additionally, despite controlling for poten-
tial confounders, residual confounding by factors not
measured in our study (e.g., thrombophilia and maternal
use of triptan and ergotamine medications) may have
influenced reported risk estimates. Prospective studies
are needed to enhance causal inferences concerning
associations between placental abruption and migraine.
The possible association between maternal migraine
and increased placental abruption risk may be explained
by the vascular disorders common to these two patholo-
gical conditions. Though not considered a vascular dis-
order, per se, migraine is associated with ischemic stroke
[36] and a cardiovascular risk profile [37-39] including
chronic systemic inflammation [38,40], abnormal vascu-
lar reactivity [41], increased platelet aggregation [42],
alterations in magnesium and calcium metabolism and
signaling [43], and an imbalance in the synthesis and
release of thromboxane and prostacyclin that favors
vasoconstriction [44]. Furthermore, identification of a
migraine-specific gene at chromosome 19p13, known to
be associated with missense mutations in the brain-spe-
cific P/Q-type Ca2+ channel alpha1-subunit gene, CAC-
NA1A [45], raises the possibility that genetic regulators
of calcium homeostasis may contribute to determining
migraine susceptibility. Of note, many of the pathophy-
siological features of migraine overlap with those com-
monly noted in pregnancies complicated by placental
abruption and other related perinatal disorders including
preeclampsia and preterm delivery. Finally, investigators
have speculated that migraine that persists during the
second and third trimesters in pregnancy may be in part
attributable to impaired placental function [26] and
synthesis of hormones/opioids that generally account for
the attenuation of migraine symptoms normally
observed during pregnancy [46]. Evidence from placen-
tal ultrasound studies [47], and from those that docu-
ment alterations in the synthesis and release of placental
hormones [48] and other biomarkers [49] in placental
abruption cases versus control pregnancies supports this
hypothesis.
Conclusions
Our results suggest that the risk of placental abruption
is increased in women having migraine prior to or dur-
ing pregnancy. Prospective cohort studies, however, are
needed to more rigorously evaluate the extent to which
migraine and/or its treatments are associated with the
occurrence of placental abruption. Results from studies
that allow for characterizing migraine history according
to age of onset, frequency, and triggers of migraine epi-
sodes will likely yield new information that can be used
to develop strategies for the prevention and control of
migraine and placental abruption in reproductive-aged
women. Our results add to the evolving literature that
suggests that pregnant migraineurs should be considered
at high risk for developing pregnancy complications
Table 4 Unadjusted and Adjusted Odds Ratio (OR) and 95% Confidence Interval (CI) for Placental Abruption in
Relation to Maternal History of Headaches/Migraine and Hypertensive Status, Lima, Peru, 2006-2008
Headaches/Migraine & Depression Status Placental Abruption
Cases (N = 375)
n
Controls (N = 368)
n
1Adjusted
OR (95% CI)
No Hypertension & No Depression 168 248 1.00 (referent)
Yes Hypertension/Migraine & No Depression 26 21 1.91 (1.03-3.56)
No Hypertension/Migraine & Yes Depression 57 11 7.46 (3.77-14.75)
Yes Hypertension/Migraine & Yes Depression 18 2 13.83 (3.13-61.11)
P-value for the multiplicative interaction term 0.92
1Adjusted by maternal age, education, smoking status, alcohol consumption and prenatal care utilization.
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Page 7 of 9[16,25,26]. Preconception counseling, important for
women with any medical conditions including migraine,
may provide opportunities for optimizing control of
migraine symptoms with the lowest effective doses of
the lowest number of medications; or if appropriate,
with non-pharmacological treatment including biofeed-
back-assisted relaxation, hydration, improved sleep
hygiene and reductions in occupational and home
activities.
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